Oversight of NIH and FDA: Bioethics and the Adequacy of Informed Consent : Hearing Before the Subcommittee on Human Resources of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fifth Congress, First Session, May 8, 1997
U. S. Government Staff, United States. Congress. House. Committee on Government Reform and Oversight. Subcommittee on Human Resources
U.S. Government Printing Office, 1997 - Bioethics - 228 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
activities additional agencies appropriate approved asked believe benefits bioethics biomedical Chairman clinical Committee concerns conducted CONGRESS THE LIBRARY consent form continue Department developing Director discussion drug effective efforts ethical evaluate fact Federal funding give going Health hepatitis human subjects important individuals infection informed consent Institute interest interventions involved issues Letter LIBRARY OF CONGRESS look meeting monitoring NBAC obtain Office OPRR oversight participation particular patients PENDERGAST persons policies populations potential prevent principles problem procedures proposed protection protocols question reason receive record regulations representative research subjects responsibility result review boards risk rule severe mental illnesses SHAYS specific staff standards Subcommittee sure Thank things TOWNS treatment trials understand University vaccine Varmus WILFOND
Page 56 - ... any medical treatments are available if injury occurs and, if so, what they consist of, or where further information may be obtained; 7. An explanation of whom to contact for answers to pertinent questions about the research and research subjects' rights, and whom to contact in the event of a research-related injury to the subject; and 8.
Page 91 - ... rights, and whom to contact in the event of a research-related injury to the subject; and (8) A statement that participation is voluntary, refusal to participate will involve no penalty or loss of benefits to which the subject is otherwise entitled...
Page 179 - IRB finds that: a. the risk represents a minor increase over minimal risk; b. the intervention or procedure presents experiences to subjects that are reasonably commensurate with those inherent in their actual or expected medical, dental, psychological, social or educational situations; c. the intervention or procedure is likely to yield generalizable knowledge about the subjects...
Page 119 - Given these persistent and growing concerns about immunization safety, the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) recognized the need for an independent, expert group to address immunization safety in a timely and objective manner.
Page 64 - ... 1 . A statement that the study involves research, an explanation of the purposes of the research and the expected duration of the subject's participation, a description of the procedures to be followed, and identification of any procedures which are experimental; 2. A description of any reasonably foreseeable risks or discomforts to the subject; 3.
Page 178 - Minimal risk means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.
Page 64 - A disclosure of appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the subject; (5) A statement describing the extent, if any, to which confidentiality of records identifying the subject will be maintained...
Page 153 - Chairman, Subcommittee on Human Resources and Intergovernmental Relations Committee on Government Reform and Oversight US House of Representatives Washington, DC 20515-6143 Dear Mr.
Page 88 - The intervention under investigation must be administered before consent from the subjects' legally authorized representatives is feasible; and (iii) There is no reasonable way to identify prospectively the individuals likely to become eligible for participation in the clinical investigation. (3) Participation in the research holds out the prospect of direct benefit to the subjects because: (i) Subjects are facing a life-threatening situation that necessitates intervention; (ii) Appropriate animal...